The three DUX4 target gene biomarkers all discriminated FSHD from controls; however, none discriminated between isogenic TIRM− and TIRM+ FSHD samples on paired analysis at the 5% significance level (Fig. 2B–D). This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.